Kygevvi
Customize your policy alerts
Sign up for Cigna Policy IP0780 alerts
Get alerted when Policy IP0780 changes without checking for updates manually.
Monitor payer policy activity
This policy governs prior authorization and medical necessity criteria for coverage of Kygevvi for treatment of thymidine kinase 2 deficiency (TK2d) under Cigna-administered health benefit plans. It affects prescribers and payers evaluating requests for Kygevvi.
No material clinical or coverage changes in this revision.
Coverage Criteria for Kygevvi (TK2d)
Initial Therapy
Covered when ALL of the following are met
Approve for 1 year if all criteria met
Use of Kygevvi for any indication other than thymidine kinase 2 deficiency (TK2d) is considered not medically necessary.
Kygevvi for any other use is considered not medically necessary.
Coding and Diagnosis
| No codes listed |
What Providers Must Do
Prior authorization required
Prior authorization is required for benefit coverage of Kygevvi. All approvals are provided for the duration noted — approve for 1 year when the criteria are met. Kygevvi must be prescribed by or in consultation with a physician who specializes in the condition being treated (e.g., neurologist, geneticist, or metabolic/neuromuscular specialist).
Specialist prescribing/consultation required
Prescriptions for Kygevvi must be authored or made in consultation with an appropriate specialist because specialized skills are required for evaluation, diagnosis, monitoring of adverse events, and assessment of long-term efficacy.
- Specialist examples: neurologist, geneticist, or physician specializing in metabolic and/or neuromuscular disorders
- Approval requires specialist involvement as stated in the policy statement and FDA‑approved indication criteria
Documentation required: genetic confirmation and supporting records
Provide genetic test results that confirm biallelic pathogenic or likely pathogenic variants in the TK2 gene and any supporting chart notes or records. All documentation must include patient‑specific identifying information.
- Genetic test confirming biallelic pathogenic or likely pathogenic TK2 variants is required (noted as [documentation required])
- Acceptable documentation may include chart notes, laboratory tests, claims records, prescription receipts, and other information
Denial triggers: unsupported diagnosis or non‑TK2d use
Claims submitted without covered diagnosis or procedure codes, or for uses other than thymidine kinase 2 deficiency (TK2d), will be denied as not covered/not medically necessary.
- Claims billed for conditions or diagnoses not covered under this policy will be denied
- Kygevvi for any indication other than TK2d is considered not medically necessary
Initial Therapy Criteria
Initial Therapy — Initial approval criteria
Initial approval criteria
Approve for 1 year
Continuation / Renewal Criteria
Continuation Therapy
Continuation/renewal
Key Definitions
Background
Thymidine kinase 2 deficiency (TK2d) is an ultra-rare, progressive mitochondrial myopathy caused by autosomal recessive TK2 mutations leading to impaired mitochondrial DNA maintenance, progressive proximal muscle weakness, respiratory insufficiency, and high morbidity and mortality, particularly with earlier symptom onset. Diagnosis is based on clinical features and requires genetic confirmation with biallelic pathogenic or likely pathogenic TK2 variants.
This policy governs prior authorization and medical necessity criteria for coverage of Kygevvi for treatment of TK2d under Cigna-administered health benefit plans; prior authorization is required and approvals are provided for 1 year when criteria are met.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.